Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia

29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...

Read more →

ObsEva announces UK MHRA marketing authorisation for Yselty (linzagolix), an oral GnRH antagonist, for the treatment of uterine fibroids

28 June 2022 - Theramex to commercialise Yselty; ObsEva to receive royalties on commercial sales, as well as development, commercial, and ...

Read more →

NICE publishes its 800th technology assessment

29 June 2022 - TAs 799 and 800 are for the same technology. ...

Read more →

The Innovative Medicines Fund - good news for patients but has an opportunity been missed to be more ambitious?

27 June 2022 - NHS England and Improvement has announced the launch of the Innovative Medicines Fund. The ABPI’s Director ...

Read more →

Positive MHRA decision for Briviact

24 June 2022 - MHRA extends UCB’s therapy for the treatment of partial-onset seizures. ...

Read more →

Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy

23 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

23 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

NICE opts to reject Acorda’s MS drug Fampyra

22 June 2022 - NICE has announced its decision to reject Fampyra – also known as fampridine – for use ...

Read more →

Slow release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis

21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using slow-release ...

Read more →

EQRx announces acceptance of marketing authorisation application by the UK's Medicines and Healthcare Products Regulatory Agency for aumolertinib in EGFR mutated non-small-cell lung cancer

14 June 2022 - Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR ...

Read more →

Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma

21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using tebentafusp ...

Read more →

NICE recommends new targeted treatment for early breast cancer

16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...

Read more →

NHS lands breakthrough in global battle against superbugs

15 June 2022 - The NHS is set to roll out two ‘superbug’ busting drugs through a world first, pioneering ...

Read more →

MHRA joins international partnerships to set global standards for medicines and medical devices regulation

16 June 2022 - These are the International Medical Device Regulatory Forum, the International Council for Harmonisation of Technical Requirements for ...

Read more →

Savara awarded innovation passport in United Kingdom for molgramostim nebuliser solution, a novel investigational inhaled biologic

16 June 2022 - Innovation passport awarded to molgramostim for the treatment of auto-immune pulmonary alveolar proteinosis, a rare lung disease. ...

Read more →